| value |
{"aggregator_url":"https://www.sec.gov {"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1367083/0001683168-26-003052.txt","as_of":"2026-04-18T03:05:05.644967+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1367083/0001683168-26-003052.txt","company":"Sonoma Pharmaceuticals, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1367083/0001683168-26-003052.txt","article_chars":4999,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_629eb5c92d19cfbc","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1367083/0001683168-26-003052.txt","content_type":"text/plain","enriched_at":"2026-04-18T03:40:59.251311+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1367083/0001683168-26-003052.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1367083/0001683168-26-003052.txt","source_event_id":"evt_2164a6f99cbb","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"S-1","fp":"1f4cab2b41f114c1","kind":"sec_filing","published_at":"20260417","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-17","2026-04-09","18, 2026"],"entities":[{"asset_class":"equity","name":"Sonoma Pharmaceuticals, Inc.","relevance":"high","symbol":"","type":"issuer"},{"asset_class":"regulation","name":"U.S. Securities and Exchange Commission","relevance":"high","symbol":"","type":"regulator"}],"event_type":"listing","information_gaps":["What changed vs prior known state is not provided in the signal (no prior filing details to compare).","Key offering terms are placeholders in the provided text (e.g., number of units/shares [\u25cf], offering price $ per unit, warrant exercise price $[\u25cf], and the pre-funded warrant price reduction $[\u25cf]).","The filing\u2019s \u201cmaterial_items\u201d are not extracted because the provided text excerpt does not include specific financial statements, risk factors, or item-by-item disclosures.","The excerpt cuts off mid-sentence regarding pre-funded warrant exercisability/expiration (\u201cuntil all of the\u2026\u201d), so the full pre-funded warrant term is not available in the provided text."],"key_facts":["The document is a Form S-1 registration statement under the Securities Act of 1933.","It is dated April 9, 2026 and filed with the SEC on April 17, 2026 (as stated: \u201cAs filed\u2026 on April 17, 2026\u201d).","The offering is described as up to [\u25cf] units in a firm commitment underwritten public offering.","Each unit consists of one share of common stock (par value $0.0001 per share) and one warrant to purchase one share of common stock.","The assumed offering price is stated as $ per unit, \u201cequal to the closing price of our common stock on the Nasdaq Capital Market on 18, 2026,\u201d with gross proceeds of approximately $5 million; the exact price is shown as a placeholder [\u25cf]/$ per unit.","Each common warrant\u2019s exercise price is stated as $[\u25cf] per share, \u201cequal to 100% of the public offering price of each unit sold in this offering.\u201d","Each warrant is exercisable immediately and expires five years from the date of issuance.","The filing provides for pre-funded warrants in lieu of shares for purchasers whose beneficial ownership would exceed 4.99% (or 9.99% at the purchaser\u2019s election) immediately after the offering.","The purchase price of each pre-funded warrant and accompanying warrant equals the public price per share and accompanying warrant minus $[\u25cf].","Each pre-funded warrant has an exercise price of $0.0001 per share and is immediately exercisable; the text provided cuts off before stating the full expiration/termination terms."],"numeric_claims":[{"label":"gross proceeds (stated)","value":"approximately $5 million"},{"label":"common stock par value","value":"$0.0001 per share"},{"label":"warrant term","value":"5 years from date of issuance"},{"label":"beneficial ownership threshold","value":"4.99% (or 9.99% at election)"},{"label":"pre-funded warrant exercise price","value":"$0.0001 per share"}],"primary_claim":"Sonoma Pharmaceuticals, Inc. filed a Form S-1 registration statement on April 17, 2026 to register a proposed underwritten public offering of units consisting of common stock and warrants.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"Sonoma Pharmaceuticals, Inc. filed a Form S-1 registration statement with the SEC on April 17, 2026. The filing describes a proposed underwritten public offering of units combining common stock and warrants, with gross proceeds stated as approximately $5 million (with key pricing terms left as placeholders).","topics":["SEC filing","Form S-1","public offering","common stock","warrants","pre-funded warrants","underwritten offering","beneficial ownership limitation"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form S-1 \u00b7 Sonoma Pharmaceuticals, Inc. \u00b7 Filed 20260417","ticker":"SNOA","tickers":["SNOA"],"title":"SNOA filed S-1","url":"https://www.sec.gov/Archives/edgar/data/1367083/0001683168-26-003052.txt"}... |